The John Hancock Tax-Advantaged Dividend Income Fund (HTD) is currently trading at a discount of over 10%, making it an attractive option for long-term income investors. The fund, which focuses on utilities and fixed income, has faced pressure from rising interest rates and widening discounts, leading to underperformance. Despite this, HTD maintains a stable and diversified portfolio with essential sector exposure, presenting a compelling opportunity for investors seeking steady income. The fund's historically wide discount and monthly payouts add to its appeal for those looking to smooth income streams and benefit from faster compounding.
The John Hancock Tax-Advantaged Dividend Income Fund (HTD) market context as of Oct 17, 2026 01:21 WIB shows a broad decline among US stocks on Pluang, with 44 rising and 104 falling out of 150 priced stocks. Notable movers include FCEL at USD 12.87 with a 1-day change of -8.66% and a Pluang order activity of 3% Sell / 97% Buy, SNOW at USD 306.78 down 8.44% with 56% Sell / 44% Buy, and PLUG at USD 1.38 down 7.41% with 2% Sell / 98% Buy. The most notable figure is FCEL's strong buy interest despite its price drop.
Kering has released its monthly statement detailing the total number of shares and voting rights as of October 15, 2026. The company reported 123,420,778 total shares and 176,815,752 theoretical voting rights, with 176,046,302 exercisable voting righ...
Kering published its monthly update on October 15, 2026, reporting a total of 123,420,778 shares composing its capital and 176,815,752 theoretical voting rights. The voting rights figure includes all shares with voting rights, including those tempora...
Pepeto, a new cryptocurrency on the Ethereum network, has quickly raised over $11.23 million in its presale, with each funding stage closing faster than the last. This momentum comes as Ethereum is predicted to reach $10,000 by the end of 2026, drive...
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
